BioNexus Gene Lab Corp. (BGLC) Earnings History
Net Loss9 years of earnings data (2016–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
BioNexus Gene Lab Corp. (BGLC) Earnings Overview
As of June 23, 2026, BioNexus Gene Lab Corp. (BGLC) reported trailing twelve-month net income of -$2M, reflecting +41.2% year-over-year growth. The company earned $-1.28 per diluted share over the past four quarters, with a net profit margin of -16.8%.
Looking at the long-term picture, BGLC's historical earnings data spans multiple years. The company achieved its highest annual net income of $1M in fiscal 2020.
BioNexus Gene Lab Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including QDEL (-$1.21B net income, -41.5% margin), CLOV (-$57M net income, -4.4% margin), RNAZ (-$40M net income), BGLC has outperformed on profitability metrics. Compare BGLC vs QDEL →
BGLC Earnings vs Peers
Earnings metrics vs comparable public companies
BGLC Historical Earnings Data (2016–2024)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$2M | +39.2% | -$2M | $-0.90 | -16.8% | -16.5% |
| 2023 | -$3M | -638.6% | -$3M | $-1.53 | -26.9% | -26.5% |
| 2022 | $-355,966 | -147.4% | $-291,177 | $-0.25 | -3.3% | -2.7% |
| 2021 | $751,571 | -31.3% | $1M | $0.53 | 5.6% | 7.9% |
| 2020 | $1M | +543.9% | $1M | $1.28 | 9.6% | 11.2% |
| 2019 | $-246,469 | -1031.7% | $-275,705 | $-0.03 | -194.1% | -217.2% |
| 2018 | $26,454 | +121.4% | $59,901 | $0.00 | 12.5% | 28.2% |
| 2017 | $-123,750 | -14720.4% | $-127,910 | $-0.02 | -114.9% | -118.8% |
| 2016 | $-835 | - | $-840 | $-0.00 | - | - |
Download Data
Export BGLC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BGLC — Frequently Asked Questions
Quick answers to the most common questions about buying BGLC stock.
What is BGLC earnings per share (EPS)?
BGLC trailing twelve-month (TTM) diluted EPS is $-1.28, reflecting +41.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2024 is available in the table on this page.
What is BioNexus Gene Lab Corp.'s net income?
BioNexus Gene Lab Corp. (BGLC) trailing twelve-month net income is $-2M as of 2024. Earnings grew +41.2% year-over-year.
Is BGLC profitable?
BGLC is not currently profitable on a TTM basis, reporting a net loss of $-2M. Net margin is -16.8%. Investors should monitor for a return to profitability.
What is BGLC's earnings growth rate?
BGLC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2024.
What are BGLC's profit margins?
BioNexus Gene Lab Corp. net profit margin is -16.8%, operating margin is -16.5%, and gross margin is +13.6%. Below-average margins reflect competitive or cost pressures. Return on Equity is -17.8%.
Is BGLC growing earnings?
Yes, BGLC earnings are accelerating — EPS growth of +41.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-2M. Earnings momentum is strengthening.
What was BGLC's best earnings year?
BioNexus Gene Lab Corp.'s highest annual net income on record is $1M, achieved in fiscal year 2020. Earnings history on this page spans 2016 to 2024 and includes all annual and quarterly figures.
What were BGLC's earnings last quarter?
BGLC's most recent reported quarter was Q3 2025. Net income was $-708991.00 with diluted EPS of $-0.39. For a full breakdown of all quarters, see the quarterly earnings table on this page.